Daewoong Pharmaceutical announced that the company aims for annual sales of its two new drugs, gastroesophageal reflux treatment Fexuclue and diabetes drug Envlo, to reach 1 trillion won ($736 million) by 2030. "Daewoong Pharmaceutical anticipates new launches and outlicensing deals involving Fexuclue and Envlo in the global pharmaceutical market," said Kim Do-young, head of Daewoong Pharmaceutical's G.
Kim Do-young-IV (김도영) hancinema.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hancinema.net Daily Mail and Mail on Sunday newspapers.